

I hereby certify that this correspondence is being deposited with the United States Postal ervice as first class\_mail in an envelope addressed to: Commissioner for Patents, Washington,

9 C. 20231 on August 4, 2003.

Stephen A Slusher, Reg. No. 43,924

August 4, 2003 (Date Signed)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Christine H. Blood,

Annette M. Shadiack, Joanna K. Bernstein,

and Guy W. Herbert

Examiner: C. Kam

Serial No.:

10/040,547

Group Art Unit: 1653

Filed:

January4; 2002

For: COMPOSITIONS AND METHODS FOR TREATMENT OF SEXUAL DYSFUNCTION

## TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT BEFORE MAILING OF FIRST OFFICE ACTION WITH INFORMATION DISCLOSURE STATEMENT AS CITED IN A COMMUNICATIONS FROM A FOREIGN PATENT OFFICE (37 CFR § 1.97)

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

The Information Disclosure Statement submitted herewith is being filed before the mailing date of a first Office Action on the merits. 37 CFR § 1.97(b).

Dated: August 4, 2002

Stephen A Slusher Reg. No. 43,924

Direct line: (505) 998-6130

Attorneys for Applicant(s)
PEACOCK, MYERS& ADAMS, P.C.
P.O. BOX 26927
Albuquerque, New Mexico 87125-6927

Telephone: (505) 998-1500 Facsimile: (505) 243-2542

File: 70025-9904

[G:\Mike\PATENT\Palatin-Rhomed\S xDysfunc-CIP\IDS Trans3.EPO.doc]

Please type	a plus sign (+)	inside this box	<b>→</b>	+
-------------	-----------------	-----------------	----------	---

PTC/SB/08A (08-00)
Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known			
Application Number	10/040,547	_	
Filing Date	January 4, 2002		
First Named Inventor	BLOOD, Christine		
Group Art Unit	1653		
Examiner Name	C. Kam	_	
Attorney Docket Number	70025-04-CIP	_	

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	U.S. Patent Document  Kind Code <sup>2</sup> (# known)		Name of Patentee or Applicant	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		4,649,191		Hruby	03/10/1987		
		5,420,109	oxdapprox	Suto, et al.	05/30/1995		
			┼		+		
			+-				
			+-				
			—				
			+-		+		
			+-				
			╀		<u> </u>		
			╄		<del> </del>		
			$\vdash$		<del>    -   -   -   -   -   -   -   -  </del>		
			T				
		<del> </del>	1				

			FOR	EIGN PATENT DOCUMENT	rs		
aminer Cite			Kind Code <sup>s</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sub>6</sub>
	FR	2 691 465		Fabre Medicament	11-26-1993		
	FR	2 735 131		Societe D'Etude et	12-13-1996		
				de Recherche de			
				Pathologie Applique			
				Serpa Societe Civile			
	PCT	WO 94/22460		Univ. Patents, Inc.	10-13-1994		-
	-				<del> </del>		-
		No.¹ Office:	No.1 Office3 Number4	Cite No.¹ Office³ Number⁴ (# known)  FR 2 691 465  FR 2 735 131	Cite No.1 Office3 Number4 (# known)  FR 2 691 465 Fabre Medicament  FR 2 735 131 Societe D'Etude et de Recherche de Pathologie Applique  Serpa Societe Civile	Cite No.1 Office3 Number4 KInd Code3 (If known) Applicant of Cited Document MM-DD-YYYY  FR 2 691 465 Fabre Medicament 11-26-1993  FR 2 735 131 Societe D'Etude et 12-13-1996  de Recherche de Pathologie Applique  Serpa Societe Civile	Cite No. 1 Office 3 Number 4 (# known) Name of Patentee or Applicant of Cited Document MM-DD-YYYY  FR 2 691 465 Fabre Medicament 11-26-1993  FR 2 735 131 Societe D'Etude et de Recherche de Pathologie Applique  Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear  11-26-1993  Societe D'Etude et 12-13-1996  Pathologie Applique  Serpa Societe Civile

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box ->	+
--	---

PTC/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

ander the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

10/040,547 **Application Number** January 4, 2002 Filing Date BLOOD, Christin **First Named Inventor** 1653 Group Art Unit Kam **Examiner Name** 

Complete if Known

(use as many sheets as necessary) of Sheet 2

**Attorney Docket Number** 70025-04-CIP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*					
		Low, et al., "Role of Chain Termini in Selective Steroidogenic Effect of ACTH MSh-4-10 on Isolated Adrenocortical Cells," PEPTIDES (Elmsford), Vol. 11, No. 1, 1990, pp. 29-32			
·					
			<u>                                     </u>		
	-	·	+		
			-		
			$\downarrow$		

Examiner	Date
Signature	Considered
o.g. a.c.	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.